Pituitary-thyroid function in spironolactone treated hypertensive women.
Four weeks high dose spironolactone treatment (Aldactone Searle, 100 mg q. i. d.) significantly enhanced the TSH (delta max. 8.5 +/- 4.1 vs. 4.6 +/- 3.1 microunits/ml, P less than 0.05) and T3 (delta max. 32 +/- 27 vs. 11 +/- 16 ng/100 ml, P less than 0.05) responses to an intravenous TRH/LH-RH bolus injection in 6 eumenorrhoeic euthyroid hypertensive women, without affecting basal serum TSH, T3 or T4 levels or the basal and stimulated LH, FSH and prolactin values (P greater than 0.10). The mean serum testosterone, 17-hydroxyprogesterone and oestradiol levels were also similar before and during therapy. Spironolactone, possibly by virtue of its antiandrogenic action, may exert its enhancing effect on pituitary-thyroid function by modulating the levels of receptors for TRH in the thyrotrophs or by altering the T3 receptor in the pituitary permitting a greater response to TRH.
D000328:Adult; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D006908:Hydroxyprogesterones / Q000097:blood; D006973:Hypertension / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D010902:Pituitary Gland / Q000187:drug effects*; D011388:Prolactin / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects* / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood; D013961:Thyroid Gland / Q000187:drug effects*; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone
D006908:Hydroxyprogesterones; D013148:Spironolactone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin